Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.

O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators.

J Clin Oncol. 2019 Mar 10;37(8):613-623. doi: 10.1200/JCO.18.00899. Epub 2019 Feb 1.

PMID:
30707661
2.

Pillars Article: Purification of a Human Monocyte-Derived Neutrophil Chemotactic Factor That Has Peptide Sequence Similarity to Other Host Defense Cytokines. Proc. Natl. Acad. Sci. USA 1987. 84: 9233-9237.

Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ.

J Immunol. 2019 Jan 1;202(1):5-9. No abstract available.

PMID:
30587568
3.

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.

Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ.

JAMA Oncol. 2019 Jan 1;5(1):e183773. doi: 10.1001/jamaoncol.2018.3773. Epub 2019 Jan 10.

PMID:
30347019
4.

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.

Kelly KR, Friedberg JW, Park SI, McDonagh K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, Stefanovic A, Bernstein SH, Weitman S, Karnad A, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D.

Clin Cancer Res. 2018 Dec 15;24(24):6150-6159. doi: 10.1158/1078-0432.CCR-18-0286. Epub 2018 Aug 6.

PMID:
30082475
5.

Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.

Graff JN, Higano CS, Hahn NM, Taylor MH, Zhang B, Zhou X, Venkatakrishnan K, Leonard EJ, Sarantopoulos J.

Cancer. 2016 Aug 15;122(16):2524-33. doi: 10.1002/cncr.30073. Epub 2016 May 18.

6.

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH.

J Clin Oncol. 2014 Jan 1;32(1):44-50. doi: 10.1200/JCO.2012.46.8793. Epub 2013 Sep 16.

7.
8.

The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation.

Angeloni D, Danilkovitch-Miagkova A, Miagkov A, Leonard EJ, Lerman MI.

J Biol Chem. 2004 Jan 30;279(5):3726-32. Epub 2003 Nov 3.

9.

Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway.

Danilkovitch-Miagkova A, Miagkov A, Skeel A, Nakaigawa N, Zbar B, Leonard EJ.

Mol Cell Biol. 2001 Sep;21(17):5857-68.

10.

Anti-apoptotic action of macrophage stimulating protein (MSP).

Danilkovitch-Miagkova A, Leonard EJ.

Apoptosis. 2001 Jun;6(3):183-90. Review.

PMID:
11388667
11.

Cross-talk between RON receptor tyrosine kinase and other transmembrane receptors.

Danilkovitch-Miagkova A, Leonard EJ.

Histol Histopathol. 2001 Apr;16(2):623-31. doi: 10.14670/HH-16.623. Review.

PMID:
11332718
12.
13.

Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples.

Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, Breathnach R, Johnson BE, Leonard EJ, Lerman MI.

Genes Chromosomes Cancer. 2000 Oct;29(2):147-56.

PMID:
10959094
14.

Integrin-mediated RON growth factor receptor phosphorylation requires tyrosine kinase activity of both the receptor and c-Src.

Danilkovitch-Miagkova A, Angeloni D, Skeel A, Donley S, Lerman M, Leonard EJ.

J Biol Chem. 2000 May 19;275(20):14783-6.

15.
16.

Macrophage stimulating protein.

Leonard EJ, Danilkovitch A.

Adv Cancer Res. 2000;77:139-67. Review. No abstract available.

PMID:
10549357
18.
19.

Kinases involved in MSP/RON signaling.

Danilkovitch A, Leonard EJ.

J Leukoc Biol. 1999 Mar;65(3):345-8. Review.

PMID:
10080538
20.

Characterization of free alpha- and beta-chains of recombinant macrophage-stimulating protein.

Yoshikawa W, Hara H, Takehara T, Shimonishi M, Sakai H, Shimizu N, Shimizu S, Wang MH, Hagiya M, Skeel A, Leonard EJ.

Arch Biochem Biophys. 1999 Mar 15;363(2):356-60.

PMID:
10068459
21.

Proteolytic cleavage and activation of pro-macrophage-stimulating protein and upregulation of its receptor in tissue injury.

Nanney LB, Skeel A, Luan J, Polis S, Richmond A, Wang MH, Leonard EJ.

J Invest Dermatol. 1998 Oct;111(4):573-81.

22.
23.

Macrophage stimulating protein (MSP) binds to its receptor via the MSP beta chain.

Wang MH, Julian FM, Breathnach R, Godowski PJ, Takehara T, Yoshikawa W, Hagiya M, Leonard EJ.

J Biol Chem. 1997 Jul 4;272(27):16999-7004.

24.

Biological aspects of macrophage-stimulating protein (MSP) and its receptor.

Leonard EJ.

Ciba Found Symp. 1997;212:183-91; discussion 192-7. Review.

PMID:
9524771
25.

Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein.

Wang MH, Montero-Julian FA, Dauny I, Leonard EJ.

Oncogene. 1996 Nov 21;13(10):2167-75.

PMID:
8950984
26.
27.
28.

Macrophage-stimulating protein induces proliferation and migration of murine keratinocytes.

Wang MH, Dlugosz AA, Sun Y, Suda T, Skeel A, Leonard EJ.

Exp Cell Res. 1996 Jul 10;226(1):39-46.

PMID:
8660937
31.

Macrophage-stimulating protein activates Ras by both activation and translocation of SOS nucleotide exchange factor.

Li BQ, Wang MH, Kung HF, Ronsin C, Breathnach R, Leonard EJ, Kamata T.

Biochem Biophys Res Commun. 1995 Nov 2;216(1):110-8.

PMID:
7488076
32.

Terminal differentiation of murine resident peritoneal macrophages is characterized by expression of the STK protein tyrosine kinase, a receptor for macrophage-stimulating protein.

Iwama A, Wang MH, Yamaguchi N, Ohno N, Okano K, Sudo T, Takeya M, Gervais F, Morissette C, Leonard EJ, Suda T.

Blood. 1995 Nov 1;86(9):3394-403.

PMID:
7579443
33.

The murine stk gene product, a transmembrane protein tyrosine kinase, is a receptor for macrophage-stimulating protein.

Wang MH, Iwama A, Skeel A, Suda T, Leonard EJ.

Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3933-7.

34.

Normal human sweat contains interleukin-8.

Jones AP, Webb LM, Anderson AO, Leonard EJ, Rot A.

J Leukoc Biol. 1995 Mar;57(3):434-7.

PMID:
7884315
35.

Identification of the ron gene product as the receptor for the human macrophage stimulating protein.

Wang MH, Ronsin C, Gesnel MC, Coupey L, Skeel A, Leonard EJ, Breathnach R.

Science. 1994 Oct 7;266(5182):117-9.

PMID:
7939629
37.

Macrophage-stimulating protein inhibits induction of nitric oxide production by endotoxin- or cytokine-stimulated mouse macrophages.

Wang MH, Cox GW, Yoshimura T, Sheffler LA, Skeel A, Leonard EJ.

J Biol Chem. 1994 May 13;269(19):14027-31.

38.

Action and target cell specificity of human macrophage-stimulating protein (MSP).

Skeel A, Leonard EJ.

J Immunol. 1994 May 1;152(9):4618-23.

PMID:
8157975
40.

Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma.

Kuratsu J, Yoshizato K, Yoshimura T, Leonard EJ, Takeshima H, Ushio Y.

J Natl Cancer Inst. 1993 Nov 17;85(22):1836-9.

PMID:
8230263
41.

Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium.

Harigai M, Hara M, Yoshimura T, Leonard EJ, Inoue K, Kashiwazaki S.

Clin Immunol Immunopathol. 1993 Oct;69(1):83-91.

PMID:
8403545
42.

Antibodies to macrophage stimulating protein (MSP): specificity, epitope interactions, and immunoassay of MSP in human serum.

Wang MH, Skeel A, Yoshimura T, Copeland TD, Sakaguchi K, Leonard EJ.

J Leukoc Biol. 1993 Oct;54(4):289-95.

PMID:
7691976
43.
45.
46.

Secretion of monocyte chemoattractant protein-1 (MCP-1) by human mononuclear phagocytes.

Leonard EJ, Skeel A, Yoshimura T, Rankin J.

Adv Exp Med Biol. 1993;351:55-64. Review.

PMID:
7942299
47.

Evaluating antitrust risk in joint provider negotiations with payors.

Leonard EJ.

Med Staff Couns. 1992 Winter;6(1):41-7.

PMID:
10115450
48.

Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 antibody in normal human serum.

Sylvester I, Yoshimura T, Sticherling M, Schröder JM, Ceska M, Peichl P, Leonard EJ.

J Clin Invest. 1992 Aug;90(2):471-81.

49.

Human monocyte chemoattractant protein-1: structure and function.

Yoshimura T, Leonard EJ.

Cytokines. 1992;4:131-52. Review. No abstract available.

PMID:
1472914
50.

Production and characterization of mouse monoclonal antibodies against human monocyte chemoattractant protein-1.

Yoshimura T, Takeya M, Takahashi K, Kuratsu J, Leonard EJ.

J Immunol. 1991 Oct 1;147(7):2229-33.

PMID:
1918959

Supplemental Content

Loading ...
Support Center